Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie
PubMed
30713022
DOI
10.1016/j.rbmo.2018.12.032
PII: S1472-6483(18)30661-8
Knihovny.cz E-zdroje
- Klíčová slova
- Anti-Müllerian hormone, Follitropin delta, GnRH agonist triggering, OHSS, Ovarian stimulation, Preventive interventions,
- MeSH
- dospělí MeSH
- fertilizace in vitro MeSH
- folikuly stimulující hormon lidský aplikace a dávkování terapeutické užití MeSH
- indukce ovulace * škodlivé účinky MeSH
- interpretace statistických dat MeSH
- intracytoplazmatické injekce spermie MeSH
- kryoprezervace MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- ovariální hyperstimulační syndrom prevence a kontrola MeSH
- ovarium účinky léků MeSH
- rekombinantní proteiny aplikace a dávkování terapeutické užití MeSH
- riziko MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- folikuly stimulující hormon lidský MeSH
- follitropin alfa MeSH Prohlížeč
- follitropin delta MeSH Prohlížeč
- rekombinantní proteiny MeSH
RESEARCH QUESTION: Is individualization of dosing with follitropin delta in sequential ovarian stimulation cycles an effective preventive strategy for ovarian hyperstimulation syndrome risk? If so, for which patients does an individualized strategy provide the greatest OHSS risk reduction and/or the need for additional preventive interventions? DESIGN: A secondary analysis of three ovarian stimulation cycles in IVF/intracytoplasmic sperm injection patients included in one randomized, assessor-blinded trial comparing two recombinant FSH preparations (ESTHER-1, NCT01956110), and a second trial in women undergoing up to two additional cycles (ESTHER-2, NCT01956123). Of 1326 women (aged 18-40 years) randomized and treated with follitropin delta or alfa in cycle 1, 513 continued to cycle 2 and 188 to cycle 3. Follitropin delta and alfa doses were maintained/adjusted according to ovarian response in the previous cycle. RESULTS: Individualized dosing with follitropin delta significantly reduced moderate/severe OHSS and/or preventive interventions (P=0.018) versus conventional dosing with follitropin alfa in patients undergoing up to three ovarian stimulation cycles. The greatest benefit was observed in patients in the highest anti-Müllerian hormone (AMH) quartile (P=0.012). On evaluating separately, individualized dosing with follitropin delta significantly lowered the incidences of moderate/severe OHSS (P=0.036) and preventive interventions (P=0.044) versus follitropin alfa. CONCLUSION: An individualized follitropin delta dosing regimen decreased the risk of moderate/severe OHSS as well as the incidence of preventive interventions versus a conventional follitropin alfa regimen. An analysis per AMH quartile indicated that these statistically significant differences are driven mainly by patients with the highest pretreatment AMH levels.
Ferring Pharmaceuticals US Development Parsippany NJ 07054 USA
Global Biometrics Ferring Pharmaceuticals Copenhagen 2300 Denmark
IVF CUBE SE Prague 160 00 Czech Republic
Olive Fertility Centre Vancouver V5Z 3X7 Canada
Science and Medicine Ferring Pharmaceuticals Copenhagen 2300 Denmark
Citace poskytuje Crossref.org
